ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

RHINISENG Suspension for injection for pigs.

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each dose of 2 ml contains:

**Active substances:**
- Inactivated *Bordetella bronchiseptica*, strain 833CER: .................................................. 9.8 BbCC(*)
- Recombinant Type D *Pasteurella multocida* toxin (PMTr): .................................................. ≥ 1 MED₆₃(**)

(*) *Bordetella bronchiseptica* Cell Count in log₁₀.

(**) Murine Effective Dose 63: vaccination of mice with 0.2 ml of a 5-fold diluted vaccine by subcutaneous route induces seroconversion in at least 63% of the animals.

**Adjuvants:**
- Aluminium hydroxide gel ................................................................. 6.4 mg (aluminium)
- DEAE-Dextran
- Ginseng

**Excipient:**
- Formaldehyde.......................................................................................... 0.8 mg

For a full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Suspension for injection.

4. **CLINICAL PARTICULARS**

4.1 **Target species**

Sows and gilts.

4.2 **Indications for use, specifying the target species**

For the passive protection of piglets via colostrum after active immunisation of sows and gilts to reduce the clinical signs and lesions of progressive and non-progressive atrophic rhinitis, as well as to reduce weight loss associated with *Bordetella bronchiseptica* and *Pasteurella multocida* infections during the fattening period.

Challenge studies have demonstrated that passive immunity lasts until piglets are 6 weeks of age while in clinical field trials, the beneficial effects of vaccination (reduction in nasal lesion score and weight loss) are observed until slaughter.

4.3 **Contraindications**

Do not use in case of hypersensitivity to the active substances, to the adjuvants or to any of the excipients.

4.4 **Special warnings**
4.5 Special precautions for use

Special precautions for use in animals

Vaccinate only healthy animals

Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental self-injection only a minor injection site reaction is expected.

4.6 Adverse reactions (frequency and seriousness)

Transient local reactions may occur after the administration of one dose of vaccine. A transient slight swelling of less than 2 to 3 cm in diameter is common at the injection site which may last up to five days and occasionally up to two weeks.

A transient increase in body temperature of about 0.7°C is common during the first 6 hours after injection. An increase of rectal temperature up to 1.5°C may occur. This rectal temperature increase is spontaneously resolved within 24 hours without treatment.

4.7 Use during pregnancy, lactation or lay

Can be used during pregnancy.

4.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

4.9 Amounts to be administered and administration route

Intramuscular use.

Allow the vaccine to reach room temperature (15-25°C) before administration.

Shake well before use.

Administer one dose of 2 ml by intramuscular injection in the neck muscles according to the following schedule:

Basic vaccination: sows and gilts which have not been previously vaccinated with the product should be given two injections with an interval of 3-4 weeks. The first injection should be administered 6-8 weeks before the expected date of farrowing.

Revaccination: a single injection should be given 3-4 weeks prior to each subsequent farrowing.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

No adverse reactions other than already mentioned under point 4.6 can be expected, except for an increase of rectal temperature up to 2°C. This rectal temperature increase is spontaneously resolved within 24 hours without treatment.
Discoloration of muscular fibres of the inoculation site (0.5 cm wide x 2 cm long) may be observed at necropsy in 10% of animals. This discoloration is attributable to aluminium hydroxide and may be observed up to seven weeks after the injection of a double dose of vaccine.

4.11 Withdrawal period

Zero days.

5. IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: Inactivated bacterial vaccines (Bordetella and Pasteurella) for pigs
ATCvet code: QI09AB04.

To stimulate active immunity in order to provide passive immunity to the progeny against atrophic rhinitis associated with Bordetella bronchiseptica and Pasteurella multocida infections.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Aluminium hydroxide
DEAE-dextran
Ginseng
Formaldehyde
Simethicone
Disodium phosphate dodecahydrate
Potassium dihydrogen phosphate
Sodium chloride
Potassium chloride
Water for injections

6.2 Incompatibilities

Do not mix with any other veterinary medicinal product.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: 10 hours stored at room temperature.

6.4 Special precautions for storage

Store and transport refrigerated (2 °C to 8 °C)
Protect from light.
Do not freeze.

6.5 Nature and composition of immediate packaging

Type I colourless glass vials of 20 ml
Type II colourless glass vials of 50 ml and 100 ml

The vials are closed with a rubber stopper and aluminium cap.

20 ml, 50 ml, 100 ml and 250 ml Polyethylene (PET) bottles closed with a rubber stopper and aluminium cap.
Pack sizes:
- Cardboard box with 1 or 10 glass vials of 10 doses.
- Cardboard box with 1 glass vial of 25 doses.
- Cardboard box with 1 glass vial of 50 doses.
- Cardboard box with 1 or 10 PET bottles of 10 doses.
- Cardboard box with 1 PET bottle of 25 doses.
- Cardboard box with 1 PET bottle of 50 doses.
- Cardboard box with 1 PET bottle of 125 doses.

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

LABORATORIOS HIPRA, S.A.
Avda. la Selva, 135
17170 Amer (Girona)
SPAIN
Tel. +34 972 430660
Fax. +34 972 430661
E-mail: hipra@hipra.com

8. MARKETING AUTHORISATION NUMBER(S)

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

DD/MM/YYYY

10 DATE OF REVISION OF THE TEXT

MM/YYYY

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency [http://www.ema.europa.eu/].

PROHIBITION OF SALE, SUPPLY AND/OR USE

The import, sale, supply and/or use of Rhiniseng is or may be prohibited in certain Member States on the whole or part of their territory pursuant to national animal health policy. Any person intending to import, sell, supply and/or use Rhiniseng must consult the relevant Member State’s competent authority on the current vaccination policies prior to the import, sale, supply and/or use.
ANNEX II

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE

C. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE

D. STATEMENT OF THE MRLs
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer of the biological active substances
Laboratorios Hipra, S.A.
Avda. la Selva, 135
17170 Amer (Girona)
Spain

Name and address of the manufacturer responsible for batch release
Laboratorios Hipra S.A.
Avda. la Selva, 135
17170 Amer (Girona)
Spain

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE

To be supplied only on veterinary prescription.

The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.

C. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT

Not applicable.

D. STATEMENT OF THE MRLs

The active substances being principles of biological origin intended to produce active immunity are not in the scope of Regulation (EC) 470/2009.

The following constituent of RHINISENG Suspension for injection for pigs are included in Table 1 of the Annex to Commission Regulation (EU) No 37/2010 as follows:

<table>
<thead>
<tr>
<th>Pharmacologically active substance</th>
<th>Marker residue</th>
<th>Animal species</th>
<th>MRL Target tissues</th>
<th>Other provisions</th>
<th>Therapeutic classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aluminium hydroxide</td>
<td>N/a</td>
<td>All food producing species</td>
<td>No MRL required.</td>
<td>Not applicable</td>
<td>No entry</td>
</tr>
<tr>
<td>Ginseng (standardised extracts and preparations thereof)</td>
<td>N/a</td>
<td>All food producing species</td>
<td>No MRL required.</td>
<td>Not applicable</td>
<td>No entry</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>-----</td>
<td>------------------------------------------------------</td>
<td>------------------------------</td>
<td>------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formaldehyde</td>
<td>N/a</td>
<td>No MRL required.</td>
<td>Not applicable</td>
<td>No entry</td>
<td>No entry</td>
</tr>
<tr>
<td>Simethicone</td>
<td>N/a</td>
<td>All food producing species</td>
<td>No MRL required</td>
<td>No entry</td>
<td>No entry</td>
</tr>
<tr>
<td>Simethicone (dimethicone)</td>
<td>N/a</td>
<td>All food producing species</td>
<td>No MRL required</td>
<td>N/a</td>
<td>Only substances approved as additives in foodstuffs for human consumption, with the exception of preservatives listed in part C of Annex III to European Parliament and Council Directive 95/2/EC</td>
</tr>
<tr>
<td>Disodium phosphate dodecahydrate covered by entry for food additives with an E number (E339)</td>
<td>N/a</td>
<td>All food producing species</td>
<td>No MRL required</td>
<td>N/a</td>
<td>Only substances approved as additives in foodstuffs for human consumption, with the exception of preservatives listed in part C of Annex III to European Parliament and Council Directive 95/2/EC</td>
</tr>
<tr>
<td>Potassium dihydrogen phosphate - covered by entry for food additives with an E number (E340i)</td>
<td>N/a</td>
<td>All food producing species</td>
<td>No MRL required</td>
<td>N/a</td>
<td>Only substances approved as additives in foodstuffs for human consumption, with the exception of preservatives listed in part C of Annex III to European Parliament and Council Directive 95/2/EC</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>N/a</td>
<td>All food producing species</td>
<td>No MRL required</td>
<td>N/a</td>
<td>No entry</td>
</tr>
<tr>
<td>Potassium chloride - covered by entry for food additives with an E number (E508)</td>
<td>N/a</td>
<td>All food producing species</td>
<td>No MRL required</td>
<td>N/a</td>
<td>Only substances approved as additives in foodstuffs for human consumption, with the exception of preservatives listed in part C of Annex III to European Parliament and Council Directive 95/2/EC</td>
</tr>
</tbody>
</table>

In addition to the above constituents the product contains the following excipients: DEAE-dextran and water for injection. These excipients are considered as not falling within the scope of Regulation (EC) No 470/2009.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
1. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

RHINISENG Suspension for injection for pigs.

2. **STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Per dose of 2 ml:
Inactivated *Bordetella bronchiseptica*, strain 833CER: ........................................9.8 BbCC(*)
Recombinant Type D *Pasteurella multocida* toxin (PMTr): .........................≥ 1 MED₆₃(**)

(*) *Bordetella bronchiseptica* Cell Count in log₁₀.

(**) Murine Effective Dose 63: vaccination of mice with 0.2 ml of a 5-fold diluted vaccine by subcutaneous route induces seroconversion in at least 63 % of the animals.

Aluminium hydroxide gel ................................................................. 6.4 mg (aluminium)
DEAE-Dextran
Ginseng
Formaldehyde............................................................................................... 0.8 mg

3. **PHARMACEUTICAL FORM**

Suspension for injection.

4. **PACKAGE SIZE**

1 vial of 10 doses (20 ml)
10 vials of 10 doses (20 ml)
1 vial of 25 doses (50 ml)
1 vial of 50 doses (100 ml)
1 bottle of 125 doses (250 ml)
1 bottle of 10 doses (20 ml)
10 bottles of 10 doses (20 ml)
1 bottle of 25 doses (50 ml)
1 bottle of 50 doses (100 ml)

5. **TARGET SPECIES**

Sows and gilts.

6. **INDICATIONS**

For the passive protection of piglets via colostrum after active immunisation of sows and gilts to reduce the clinical signs and lesions of progressive and non-progressive atrophic rhinitis, as well as to reduce weight loss associated with *Bordetella bronchiseptica* and *Pasteurella multocida* infections during the fattening period.

Challenge studies have demonstrated that passive immunity lasts until piglets are 6 weeks of age while in clinical field trials, the beneficial effects of vaccination (reduction in nasal lesion score and weight loss) are observed until slaughter.
7. **METHOD AND ROUTE OF ADMINISTRATION**

Intramuscular use.
Read the package leaflet before use.

8. **WITHDRAWAL PERIOD**

Withdrawal period: Zero days.

9. **SPECIAL WARNINGS, IF NECESSARY**

Read the package leaflet before use.

10. **EXPIRY DATE**

EXP {month/year}
Once opened, use within a 10 hours stored at 15ºC to 25ºC.

11. **SPECIAL STORAGE CONDITIONS**

Store and transport refrigerated
Protect from light.
Do not freeze.

12. **SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of waste material in accordance with local requirements.

13. **THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only - To be supplied only on veterinary prescription.

14. **THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”**

Keep out of the reach and sight of children.
15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

LABORATORIOS HIPRA, S.A.
Avda. la Selva, 135
17170 Amer (Girona)
SPAIN

16. MARKETING AUTHORISATION NUMBER(S)

EU/0/00/000/000 (vial)
EU/0/00/000/000 (vial)
EU/0/00/000/000 (vial)
EU/0/00/000/000 (vial)
EU/0/00/000/000 (bottle)
EU/0/00/000/000 (bottle)
EU/0/00/000/000 (bottle)
EU/0/00/000/000 (bottle)
EU/0/00/000/000 (bottle)

17. MANUFACTURER’S BATCH NUMBER

Batch {number}
1. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

RHINISENG Suspension for injection for pigs.

2. **STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

One dose of 2 ml contains:
Inactivated *Bordetella bronchiseptica*, strain 833CER: ...........................................9.8 BbCC(*)
Recombinant Type D *Pasteurella multocida* toxin (PMTr): .........................≥ 1 MED63(**)
(*) *Bordetella bronchiseptica* Cell Count in log10.
(**) Murine Effective Dose 63: vaccination of mice with 0.2 ml of a 5-fold diluted vaccine by subcutaneous route induces seroconversion in at least 63% of the animals.
Aluminium hydroxide gel ................................................................. 6.4 mg (aluminium)
DEAE-Dextran
Ginseng
Formaldehyde.............................................................................................. 0.8 mg

3. **PHARMACEUTICAL FORM**

Suspension for injection.

4. **PACKAGE SIZE**

50 doses (100 ml)
50 doses (100 ml) (bottle)
125 doses (250 ml) (bottle)

5. **TARGET SPECIES**

Sows and gilts.

6. **INDICATIONS**

For the passive protection of piglets via colostrum after active immunisation of sows and gilts to reduce the clinical signs and lesions of progressive and non-progressive atrophic rhinitis, as well as to reduce weight loss associated with *Bordetella bronchiseptica* and *Pasteurella multocida* infections during the fattening period.

Challenge studies have demonstrated that passive immunity lasts until piglets are 6 weeks of age while in clinical field trials, the beneficial effects of vaccination (reduction in nasal lesion score and weight loss) are observed until slaughter.
7. METHOD AND ROUTE OF ADMINISTRATION

Intramuscular use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Withdrawal period: Zero days.

9. SPECIAL WARNINGS, IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP {month/yyyy}

Once opened, use within a 10-hour period, stored at 15 ºC to 25 ºC.

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated
Protect from light.
Do not freeze.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only - To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”

Keep out of the reach and sight of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

LABORATORIOS HIPRA, S.A.
Avda. la Selva, 135
17170 Amer (Girona)
SPAIN
### 16. MARKETING AUTHORISATION NUMBER(S)

- EU/0/00/000/000
- EU/0/00/000/000 (bottle)
- EU/0/00/000/000 (bottle)

### 17. MANUFACTURER’S BATCH NUMBER

Batch {number}
| MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS |
| {LABEL} |

1. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

   RHINISENG Suspension for injection for pigs.

2. **QUANTITY OF THE ACTIVE SUBSTANCES**

   One dose contains:
   - Inactivated *Bordetella bronchiseptica*, strain 833CER: ............................................. 9.8 BbCC
   - Recombinant Type D *Pasteurella multocida* toxin (PMTr): .............................................≥ 1 MED$_{63}$

3. **CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

   - 10 doses (20 ml)
   - 25 doses (50 ml)

4. **ROUTE OF ADMINISTRATION**

   Intramuscular use.

5. **WITHDRAWAL PERIOD**

   Withdrawal period: Zero days.

6. **BATCH NUMBER**

   Batch {number}

7. **EXPIRY DATE**

   EXP {month/yyyy}
   Once opened, use within a 10-hour period, stored at 15 °C to 25 °C.

8. **THE WORDS “FOR ANIMAL TREATMENT ONLY”**

   For animal treatment only.
B. PACKAGE LEAFLET
1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder and manufacturer:
LABORATORIOS HIPRA, S.A.
Avda. la Selva, 135
17170 Amer (Girona)
SPAIN

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

RHINISENG Suspension for injection for pigs.

3. STATEMENT OF THE ACTIVE SUBSTANCES AND OTHER INGREDIENTS

Each dose of 2 ml contains:

Inactive B. bronchiseptica, strain 833CER: .................................................. 9.8 BbCC(*)
Recombinant Type D Pasteurella multocida toxin (PMTr): .................................. ≥ 1 MED63(**)
(*) B. bronchiseptica Cell Count in log10.
(**) Murine Effective Dose 63: vaccination of mice with 0.2 ml of a 5-fold diluted vaccine by subcutaneous route induces seroconversion in at least 63 % of the animals.
Aluminium hydroxide gel ...................................................................................... 6.4 mg (aluminium)
DEAE-Dextran
Ginseng
Formaldehyde ............................................................................................................. 0.8 mg

4. INDICATIONS

For passive protection of piglets via colostrum after active immunisation of sows and gilts to reduce the clinical signs and lesions of progressive and non-progressive atrophic rhinitis, as well as to reduce weight loss associated with B. bronchiseptica and P. multocida infections during the fattening period.

Challenge studies have demonstrated that passive immunity lasts until piglets are 6 weeks of age while in clinical field trials, the beneficial effects of vaccination (reduction in nasal lesion score and weight loss) are observed until slaughter.

5. CONTRAINDICATIONS

Do not use in case of hypersensitivity to the active substances, to the adjuvants or to any of the excipients.
6. ADVERSE REACTIONS

Transient local reactions may occur after the administration of one dose of vaccine. A transient slight swelling of less than 2 to 3 cm in diameter is common at the injection site which may last up to five days and occasionally up to two weeks.

A transient increase in body temperature of about 0.7°C is common during the first 6 hours after injection. An increase of rectal temperature up to 1.5°C may occur. This rectal temperature increase is spontaneously resolved within 24 hours without treatment.

If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.

7. TARGET SPECIES

Sows and gilts

8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

Intramuscular use.

Administer one dose of 2 ml by intramuscular injection in the neck muscles according to the following schedule:

Basic vaccination: sows and gilts which have not been previously vaccinated with the product should be given two injections with an interval of 3-4 weeks. The first injection should be administered 6-8 weeks before the expected date of farrowing.

Revaccination: a single injection should be given 3-4 weeks prior to each subsequent farrowing.

9. ADVICE ON CORRECT ADMINISTRATION

Allow the vaccine to reach room temperature (15-25°C) before administration.

Shake well before use.

10. WITHDRAWAL PERIOD

Zero days.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the reach and sight of children.
Store and transport refrigerated (2 °C to 8 °C)
Protect from light.
Do not freeze.
Do not use after the expiry date stated on the label.
Shelf life after first opening the immediate packaging: 10 hours stored at 15 °C to 25 °C.
12. SPECIAL WARNING(S)

Only healthy animals should be vaccinated.
Can be used during pregnancy.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

No adverse reactions other than already mentioned under point 6 can be expected, except for an increase of rectal temperature up to 2°C. This rectal temperature increase is spontaneously resolved within 24 hours without treatment.
Discoloration of muscular fibres of the inoculation site (0.5 cm wide x 2 cm long) may be observed at necropsy in 10% of animals. This discoloration is attributable to aluminium hydroxide and may be observed up to seven weeks after the injection of a double dose of vaccine.

Do not mix with any other veterinary medicinal product.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu/

15. OTHER INFORMATION

Pack sizes:
- Cardboard box with 1 or 10 glass vials of 10 doses.
- Cardboard box with 1 glass vial of 25 doses.
- Cardboard box with 1 glass vial of 50 doses.
- Cardboard box with 1 or 10 PET bottles of 10 doses.
- Cardboard box with 1 PET bottle of 25 doses.
- Cardboard box with 1 PET bottle of 50 doses.
- Cardboard box with 1 PET bottle of 125 doses.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

Deutschland
HIPRA DEUTSCHLAND GmbH
Feldstrasse 21
D-40479 Düsseldorf - DEUTSCHLAND

Ελλάδα
ΗΠΡΑ ΕΛΛΑΣ Α.Ε.
Ψυχόρη 3 / 184 53 Νίκαια - ΕΛΛΑΣ
Τηλ.: 210 4978660 - Fax: 210 4978661
España
LABORATORIOS HIPRA, S.A.
Avda. la Selva, 135
17170 Amer (Girona)
SPAIN

France
HIPRA FRANCE
1103 Avenue Jacques Cartier
44800 - SAINT HERBLAIN - FRANCE
Tél. - 02 51 80 77 91 Fax - 02 51 80 82 20
e-mail: france@hipra.com

Polska
HIPRA POLSKA Sp.z.o.o.
Ul. Królowej Marysienki, 9 - 1
02-954 – WARSZAWA - POLSKA
e-mail: polska@hipra.com

Portugal
ARBUSÉT, Produtos Farmacêuticos e Sanitários De Uso Animal, Lda
Portela de Mafra e Fontainha - Abrunheira
2665 – 191 Malveira - PORTUGAL
e-mail: portugal@hipra.com

United Kingdom
HIPRA UK, Ltd.
Innovation Center, Office 503
BioCity Nottingham
Pennyfoot Street
Nottingham
NG1 1GF - UNITED KINGDOM
e-mail: uk@hipra.com